Hikma And Civica Ship Eight Essential Injectables
Heparin To Be Followed By Seven Other Essential Injectable Medicines
Executive Summary
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
You may also be interested in...
Hikma’s Olafsson Sees Benefits From Broad Injectables Portfolio
Shortages are still driving growth in the US injectables market for Hikma, but the breadth of the firm’s portfolio means it has less exposure to the pressures of in-shortage products returning to market, according to CEO Siggi Olafsson.
Providers Support FDA Quest For Public Drug Manufacturing Quality Ratings
Agency agrees with those who prescribe and buy drugs on need to incentivize quality. Except providers want it yesterday.
Civica Rx Gets $55m Investment
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.